Actively Recruiting
Intra-articular Allocetra in Osteoarthritis of the of the Temporomandibular Joint (TMJ)
Led by Dr. Amit Druyan · Updated on 2024-12-27
6
Participants Needed
1
Research Sites
68 weeks
Total Duration
On this page
Sponsors
D
Dr. Amit Druyan
Lead Sponsor
S
Sheba Medical Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is a single center trial to assess the safety and initial efficacy of intra-articular administration of Allocetra to patients with Temporomandibular Joint Osteoarthritis (TMJ-OA)
CONDITIONS
Official Title
Intra-articular Allocetra in Osteoarthritis of the of the Temporomandibular Joint (TMJ)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with temporomandibular OA in the target TMJ
- Evidence of inflammation in the target TMJ seen on MRI
- Acceptable blood test results including CBC, electrolytes, kidney and liver function
You will not qualify if you...
- Received intra-articular injection to the target TMJ within 3 months before treatment
- History of significant injury or surgery to the target TMJ
- Active local infection near the target TMJ or active infection anywhere in the body
- Known neurological or rheumatic diseases, major medical conditions affecting quality of life, or unexplained pain
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sheba Medical Center
Ramat Gan, Israel
Actively Recruiting
Research Team
A
Amit Druyan, Dr.
CONTACT
T
Tehila Biton
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here